Melbourne (Australia) and Henderson, NV (U.S.A.) – 27 April 2021. Telix Pharmaceuticals Limited
(ASX: TLX, Telix, the Company) today announces that it has completed a strategic manufacturing
agreement with Global Medical Solutions, Ltd. (GMS), a global manufacturer and distributor of
diagnostic and therapeutic radiopharmaceuticals, to manufacture and supply finished unit doses of
Telix’s Molecularly Targeted Radiation (MTR) products for certain clinical development programs.

Under the terms of the agreement, GMS will initially manufacture and deliver finished unit doses of
Telix’s investigational prostate cancer therapy products TLX591 (177Lu-rosopatamab) and TLX592
to sites in Australia for Telix’s planned ProstACT Phase III and CUPID Phase I clinical trials,
respectively. The agreement is structured to support Telix’s manufacturing needs for further products
and incorporates potential future product distribution requirements in the Asia-Pacific region.

Telix Chief Executive Officer Dr. Christian Behrenbruch stated, “GMS is a dynamic nuclear medicine
company with a well-deserved reputation for manufacturing diagnostic and therapeutic
radiopharmaceutical agents to rigorous quality standards. We are pleased to have entered this
manufacturing partnership with GMS, which supports both our immediate clinical development
activities in Australia as we commence key clinical trials. Our agreement also paves the way for a
longer-term product relationship within the region, particularly in ASEAN countries where GMS is
strongly positioned in terms of regulatory expertise and market access.”

GMS Senior Vice President Operations and Business Development Shahe Bagerdjian said, “Telix
has quickly grown into a global theranostics leader with an impressive pipeline of investigational
products. We look forward to leveraging our strengths in manufacturing and distribution to support
Telix’s development of their lead prostate cancer therapy candidates in these important clinical trials
in Australia. GMS is committed to expanding access to diagnostic and therapeutic radionuclides in
Australia and more broadly in the Asia-Pacific region. We are well placed to support Telix to develop
and ultimately deliver these products to patients with prostate cancer in need.”

About Telix Pharmaceuticals Limited
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and
therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in
Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is
developing a portfolio of clinical-stage products that address significant unmet medical needs in
oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For
more information visit and follow Telix on Twitter @TelixPharma and LinkedIn.
Telix’s lead investigational product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been
accepted for filing by the U.S. FDA,1 and is under priority evaluation by the Australian Therapeutic
Goods Administration (TGA).
2 Telix is also progressing marketing authorisation applications for
Illuccix® in the European Union3 and Canada.4 None of Telix’s products have received a marketing
authorisation in any jurisdiction.

About Global Medical Solutions, Ltd.
Global Medical Solutions, Ltd. (GMS) is a leading-edge operator of centralized radiopharmacies, and
manufacturer and distributor of diagnostic and therapeutic radiopharmaceuticals and related
equipment, accessories, and services. GMS has businesses in Armenia, Australia, Brazil, China,
Hong Kong, Macau, Myanmar, New Zealand, Philippines, Russia, Taiwan, Thailand, and Vietnam,
and distributes products to over 25 countries. GMS’s diversified and vertically integrated businesses
include SPECT radiopharmacies, PET cyclotron pharmacies, Iodine-131 manufacturing centers,
cold kit manufacturing plants, medical device manufacturing plants, nuclear medicine imaging
centers, radiology products and equipment, and engineering services. For more information visit and follow GMS on LinkedIn.

1 ASX disclosure 24/11/20.
2 ASX disclosure 14/04/21.
3 ASX disclosure 1/05/20.
4 ASX disclosure 16/12/20.